Solta Medical Reports Third Quarter 2009 Results

Provides full year 2009 revenue guidance of $95 million to $98 million

HAYWARD, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (Nasdaq:
SLTM), a global leader in the medical aesthetics market, today announced
results for the third quarter ended September 30, 2009. Revenue for the
quarter was in-line with the preliminary forecast provided on September 28th.

Revenue for the third quarter was $17.8 million, an increase of approximately
$4.7 million, or 36%, as compared to the third quarter 2008 reflecting
increased revenue as a result of the acquisition of Reliant Technologies, Inc.
on December 23, 2008, and partially offset by production and regulatory
approval delays on new products during the third quarter.

"As we have previously disclosed, we received 510K clearance for the Fraxel
re:store DUAL system in mid-October and resolved our production delays on the
Thermage CPT system at the end of the third quarter. We are fulfilling back
orders from customers and shipping both products," said Stephen J. Fanning,
Chairman of the Board, President and CEO of Solta Medical. "Our illumiNATION
tour continues to bring these latest breakthroughs in Thermage and Fraxel
systems directly to physicians as it makes it way from city-to-city across the
U.S. and Europe. The tour has generated a very enthusiastic response to our
new products by physicians, prospective patients, and the media. As a result,
we are gaining momentum in the market place," added Mr. Fanning.

Solta Medical's reported results for the third quarter of 2009 include
non-cash purchase price related charges, primarily amortization of acquired
intangible assets, of $1.2 million and non-cash stock based compensation
charges of $0.8 million. The GAAP net loss for the quarter including these
charges was $6.2 million, or $0.13 per share as compared to a net loss of $1.1
million, or $0.05 per share reported for the third quarter of 2008. The
non-GAAP net loss for the quarter excluding these charges was $4.2 million, or
$0.09 per share as compared to non-GAAP net income of $0.7 million, or $0.03
per share reported for the third quarter of 2008.

Financial Goals for 2009

The Company updated its financial goals for 2009 as follows:

-- Revenue for the year in the range of $95 million to $98 million
-- Realize up to $25 million in cost synergies as a result of the
acquisition of Reliant Technologies, Inc. This represents an increase
of
$6 million from the originally stated goal in January 2009 of $19
million in cost synergies.
-- Generate positive EBITDA for the full year 2009

-- Achieve a non-GAAP gross margin in the range of 64% to 66% for the
full
year 2009 excluding non-cash amortization charges and non-cash
purchase
price related charges.

Non-GAAP Presentation

To supplement the condensed consolidated financial information presented on a
GAAP basis, management has provided non-GAAP gross margin, non-GAAP operating
income (loss), non-GAAP EBITDA, non-GAAP net income (loss) and non-GAAP
earnings (loss) per share measures that exclude the impact of purchase price
related charges, severance costs, merger related costs, extraordinary loss on
investments, and stock-based compensation expenses, all net of income taxes.
The Company believes that these non-GAAP financial measures provide investors
with insight into what is used by management to conduct a more meaningful and
consistent comparison of the Company's ongoing operating results and trends,
compared with historical results. This presentation is also consistent with
management's internal use of the measures, which it uses to measure the
performance of ongoing operating results, against prior periods and against
our internally developed targets. There are limitations in using these
non-GAAP financial measures because they are not prepared in accordance with
GAAP and may be different from non-GAAP financial measures used by other
companies. These non-GAAP financial measures should not be considered in
isolation or as a substitute for GAAP financial measures. Investors and
potential investors should consider non-GAAP financial measures only in
conjunction with the Company's consolidated financial statements prepared in
accordance with GAAP and the reconciliation of non-GAAP financial measures
attached to this release.

Conference Call Information

Solta Medical will host a conference call and webcast today, Tuesday, November
3, 2009, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss the
financial results and current corporate developments. The dial-in number for
the conference call is 877-941-1465 for domestic participants and 480-629-9678
for international participants.

A taped replay of the conference call will also be available beginning
approximately one hour after the call's conclusion and will remain accessible
for seven days. This replay can be accessed by dialing 800-406-7325 for
domestic callers and 303-590-3030 for international callers. Both callers will
need to use the Passcode 4171632#. To access the live webcast of the call, go
to Solta Medical's website at www.solta.com and click on Investor Relations.
An archived webcast will also be available at www.solta.com.

About Solta Medical, Inc.

Solta Medical, Inc. is a global leader in the medical aesthetics market
providing innovative, safe, and effective anti-aging solutions for patients
which enhance and expand the practice of medical aesthetics for physicians.

The company offers products to address aging skin under the industry's two
premier brands: Thermage(R) and Fraxel(R). Thermage is an innovative,
non-invasive radiofrequency procedure for tightening and contouring skin. As
the leader in fractional laser technology, Fraxel delivers minimally invasive
clinical solutions to resurface aging and sun damaged skin. Since 2002, over
one million Thermage and Fraxel procedures have been performed worldwide.
Thermage and Fraxel are the perfect complement for any aesthetic practice. Our
products are available in over 100 countries. For more information about Solta
Medical, call 877-782-2286 or log on to www.Solta.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of 1995, including
statements regarding our financial goals for 2009. Forward-looking statements
are based on management's current, preliminary expectations and are subject to
risks and uncertainties, which may cause Solta Medical's actual results to
differ materially from the statements contained herein. Factors that might
cause such a difference include the possibility that the market for the sale
of these new products and initiatives does not develop as expected, the
remaining risks and uncertainties with the integration process, and the risks
relating to Solta Medical's ability to achieve its stated financial goals as a
result of, among other things, economic conditions and consumer and physician
confidence causing changes in consumer and physician spending habits that
affect demand for our products and treatments. Further information on
potential risk factors that could affect Solta Medical's business and its
financial results are detailed in its Form 10-K for the year ended December
31, 2008, its Form10-Q for the quarter ended June 30, 2009, and other reports
as filed from time to time with the Securities and Exchange Commission. Undue
reliance should not be placed on forward-looking statements, especially
guidance on future financial performance, which speaks only as of the date
they are made. Solta Medical undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or circumstances
after the date they were made, or to reflect the occurrence of unanticipated
events.

Solta Medical, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands of dollars, except share and per share data)
(unaudited)

Three Months Ended Nine Months Ended
September 30, September 30,
2009 2008 2009 2008
---- ---- ---- ----

Net revenue $17,753 $13,020 $70,415 $47,132
Cost of revenue 7,311 3,209 29,595 11,662
----- ----- ------ ------
Gross margin 10,442 9,811 40,820 35,470
------ ----- ------ ------

Operating expenses:
Sales and marketing 8,958 5,915 28,471 20,330
Research and development 4,239 2,150 12,104 7,054
General and administrative 3,793 2,575 11,563 10,173
----- ----- ------ ------
Total operating expenses 16,990 10,640 52,138 37,557
------ ------ ------ ------

Loss from operations (6,548) (829) (11,318) (2,087)
Interest and other income 195 635 432 1,781
Interest and other expense (136) - (287) -
Gain (loss) on investments 159 (863) 224 (863)
--- ---- --- ----
Loss before income taxes (6,330) (1,057) (10,949) (1,169)
Provision (benefit) for
income taxes (84) 89 (13) 175
--- --- --- ---

Net loss $(6,246) $(1,146) $(10,936) $(1,344)
======= ======= ======== =======

Net loss per share - basic $(0.13) $(0.05) $(0.23) $(0.06)
====== ====== ====== ======

Net loss per share - diluted $(0.13) $(0.05) $(0.23) $(0.06)
====== ====== ====== ======

Weighted average shares
outstanding used in
calculating net loss per
share:
Basic 47,855,428 24,067,548 47,807,180 23,861,079
========== ========== ========== ==========
Diluted 47,855,428 24,067,548 47,807,180 23,861,079
========== ========== ========== ==========

Solta Medical, Inc.
NON-GAAP RECONCILIATION OF GROSS MARGIN, OPERATING INCOME (LOSS), EBITDA,
NET INCOME (LOSS) AND NET INCOME (LOSS) PER SHARE
(in thousands, except share and per share data)
(unaudited)

Three Months Ended Nine Months Ended
September 30, September 30,
2009 2008 2009 2008
---- ---- ---- ----
GAAP Gross margin $10,442 $9,811 $40,820 $35,470
Non-GAAP adjustments to
gross margin:
Purchase price related
charges 895 - 4,919 -
Stock-based compensation 61 53 175 96
--- --- --- ---
Non-GAAP gross margin $11,398 $9,864 $45,914 $35,566
======= ====== ======= =======
Non-GAAP gross margin as
% of sales 64% 76% 65% 75%
=== === === ===

GAAP loss from operations $(6,548) $(829) $(11,318) $(2,087)
Non-GAAP adjustments to
net loss from operations:
Purchase price related
charges 1,229 - 5,904 -
Severance expenses - - 118 -
Merger-related costs - 165 - 1,134
Stock-based compensation 823 887 2,476 2,789
--- --- ----- -----
Non-GAAP income (loss)
from operations $(4,496) $223 $(2,820) $1,836
Depreciation expenses 650 336 2,045 1,002
--- --- ----- -----
Non-GAAP EBITDA $(3,846) $559 $(775) $2,838
======= ==== ===== ======

GAAP net loss $(6,246) $(1,146) $(10,936) $(1,344)
Non-GAAP adjustments to
net loss:
Purchase price related
charges 1,229 - 5,904 -
Severance expenses - - 118 -
Merger-related costs - 131 - 1,075
Loss on investments - 863 - 863
Stock-based compensation 823 887 2,476 2,789
--- --- ----- -----
Non-GAAP net income (loss) $(4,194) $735 $(2,438) $3,383
======= ==== ======= ======

GAAP basic net loss per
share $(0.13) $(0.05) $(0.23) $(0.06)
Non-GAAP adjustments to
basic income (loss) per
share:
Purchase price related
charges 0.03 - 0.12 -
Severance expenses - - - -
Merger-related costs - $0.01 - 0.05
Loss on investments - $0.03 - 0.03
Stock-based compensation 0.02 $0.04 0.06 0.12
---- ----- ---- ----
Non-GAAP basic net
income (loss) per share $(0.09) $0.03 $(0.05) $0.14
====== ===== ====== =====

Non-GAAP diluted net
income (loss) per share $(0.09) $0.03 $(0.05) $0.14
====== ===== ====== =====

GAAP weighted average
shares outstanding used
in calculating basic
net loss per share 47,855,428 24,067,548 47,807,180 23,861,079
========== ========== ========== ==========

GAAP weighted average
shares outstanding used
in calculating diluted
net loss per share 47,855,428 24,067,548 47,807,180 23,861,079
Adjustments for dilutive
potential common stock - 838,410 - 1,057,632
--- ------- --- ---------
Weighted average shares
outstanding used in
calculating non-GAAP
diluted net income
(loss) per share 47,855,428 24,905,958 47,807,180 24,918,711
========== ========== ========== ==========

Solta Medical, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands of dollars, except share and per share data)
(Unaudited)

September 30, December 31,
2009 2008
---- ----

ASSETS
Current assets:
Cash and cash equivalents $14,723 $7,556
Marketable investments - 17,870
Accounts receivable, net 9,100 5,119
Inventories, net 13,363 18,304
Prepaid expenses and other current
assets 3,198 4,074
----- -----
Total current assets 40,384 52,923
Property and equipment, net 6,036 6,841
Purchased intangible assets, net 37,849 40,999
Goodwill 47,289 48,158
Other assets 265 247
--- ---

Total assets $131,823 $149,168
======== ========

LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities:
Accounts payable $5,699 $8,080
Accrued liabilities 9,838 11,085
Accrued restructuring 307 3,549
Current portion of deferred revenue 4,452 3,658
Short-term borrowings 7,411 12,399
Customer deposits 288 288
--- ---
Total current liabilities 27,995 39,059
Deferred revenue, net of current portion 526 688
Term loan, net of current portion 1,998 -
Non-current tax liabilities 1,514 1,464
Other liabilities 306 133
--- ---
Total liabilities 32,339 41,344
------ ------

Stockholders' equity:
Common stock, $0.001 par value:
100,000,000 shares authorized
47,866,829 and 47,758,823 shares issued
and outstanding at September 30, 2009
and December 31, 2008 48 48
Additional paid-in capital 168,274 165,680
Deferred stock-based compensation - (2)
Accumulated deficit (68,838) (57,902)
------- -------
Total stockholders' equity 99,484 107,824
------ -------

Total liabilities and stockholders'
equity $131,823 $149,168
======== ========

SOURCE Solta Medical, Inc.

Jack Glenn, Chief Financial Officer of Solta Medical, Inc., +1-510-786-6890;
or investors, Doug Sherk of EVC Group, +1-415-896-6820, dsherk@evcgroup.com,
for Solta Medical, Inc.